Comparative Bioavailability of Lornoxicam as Single Doses of Quick-Release Tablet, Standard Tablet and Intramuscular Injection
Tóm tắt
Background and objective: Lornoxicam is an NSAID used to obtain short-term relief of acute mild to moderate pain and symptomatic relief of pain and inflammation in rheumatoid arthritis and osteoarthritis. The aim of this study was to compare and evaluate the pharmacokinetic parameters of lornoxicam 8 mg as quick-release (QR) tablet, standard tablet (ST) and intramuscular injection (IM).
Methods: Eighteen healthy volunteers (9 male, 9 female; average age 26.9 (SD 3.0) years; average body mass index 21.8 (SD 2.3) kg/m2 were randomized to three different treatment groups. Subjects received a single 8-mg dose of each lornoxicam formulation in a three-way crossover design on days 1, 8 and 15. Lornoxicam plasma concentrations were obtained from baseline to 24 hours using high-pressure liquid chromatography. The pharmacokinetic parameters area under the plasma concentration-time curve from zero to infinity (AUC∞), maximum plasma concentration (Cmax), time to maximum plasma concentration (tmax), terminal half-life (t1/2) and mean residence time (MRT) were calculated.
Results: Lornoxicam-QR was comparable with lornoxicam-ST and lornoxicam-IM regarding AUC∞, t1/2 and MRT. The AUC∞ ratio (90% CI) was 1.07 (0.94, 1.20) for lornoxicam-QR/lornoxicam-ST and 1.10 (0.97, 1.24) for lornoxicam-QR/lornoxicam-IM. Cmax and tmax did not differ between lornoxicam-QR and lornoxicam-IM (p = 0.66 and 0.07, respectively). Both lornoxicam-QR and lornoxicam-IM showed significantly shorter tmax and significantly higher Cmax values than lornoxicam-ST.
Conclusion: Lornoxicam-QR and lornoxicam-IM did not differ with respect to AUC∞, Cmax and tmax, but both lornoxicam-QR and lornoxicam-IM showed significantly shorter tmax and significantly higher Cmax values than lornoxicam-ST.
Tài liệu tham khảo
Bernstein RM, Frenzel W. A comparative study of two dosage regimens of lornoxicam and a standard dosage of naproxen in patients with rheumatoid arthritis. Eur J Clin Res 1995; 7: 259–73
Kidd B, Frenzel W. A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis. J Rheumatol 1996; 23(9): 1605–11
Hitzenberger G, Radhofer-Welte S, Takacs F, et al. Pharmaco-kinetics of lornoxicam in man. Postgrad Med J 1990; 66Suppl. 4: S22–6
Skjodt NM, Davies NM. Clinical pharmacokinetics of lornoxicam: a short half-life oxicam. Clin Pharmacokinet 1998 Jun; 34(6): 421–8
Radhofer-Welte S, Dittrich P. Determination of the novel non-steroidal anti-inflammatory drug lornoxicam and its main metabolite in plasma and synovial fluid. J Chromatogr B Biomed Sci Appl 1998 Apr; 707(1-2): 151–9
EMEA. The Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence, CPMP/EWP/QWP/1401/98: 2001 Jun 21
Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15(6): 657–80
Kim YH, Ji HY, Park ES, et al. Liquid chromatography-electrospray ionization tandem mass spectrometric determination of lornoxicam in human plasma. Arch Pharm Res 2007 Jul; 30(7): 905–10
Yakhno N, Guekht A, Skoromets A, et al. Analgesic efficacy and safety of lornoxicam quick-release formulation compared with diclofenac potassium: randomised, double-blind trial in acute low back pain. Clin Drug Invest 2006; 26(5): 267–77
Bonnabry P, Leemann T, Dayer P. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol 1996; 49(4): 305–8
Si D, Guo Y, Zhang Y, et al. Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 2004; 14(7): 465–9
Guo Y, Zhang Y, Wang Y, et al. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos 2005; 33(6): 749–53
Mayerhofer S, Weite S, Magometschnigg D, et al. The effect of food on pharmacokinetic parameters of the new NSAID lornoxicam in healthy volunteers [abstract]. 3rd Interscience World Conference on Inflammation, Antirheumatics, Analgesics and Immunmodulators; 1989 Mar 15–18, Monte Carlo, 223